

1. Record Nr.	UNINA9910637709603321
Titolo	Cardiovascular complications of COVID-19 : acute and long-term impacts // edited by Maciej Banach
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2022] ©2022
ISBN	9783031154782 9783031154775
Descrizione fisica	1 online resource (434 pages)
Collana	Contemporary Cardiology
Disciplina	616.980214
Soggetti	Cardiovascular system - Diseases COVID-19 (Disease) - Complications
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index.
Nota di contenuto	Intro -- Foreword -- Preface -- Acknowledgments -- Contents -- Part I: General Part -- Chapter 1: Biology of SARS-CoV-2 Coronavirus -- Origin, Structure, and Variants -- Introduction -- Method of Search -- The SARS-CoV-2 Biology -- The SARS-CoV-2 Origins -- HCoV-229E -- HCoV-OC43 -- SARS-CoV -- HCoV-NL63 -- HCoV-HKU1 -- MERS-CoV -- SARS-CoV-2 -- The SARS-CoV-2 Structure -- SARS-CoV-2 Variants -- Conclusion -- References -- Chapter 2: COVID-19 Epidemiology and Differences in Incidence and Mortality Between Countries -- Origins -- Asian Countries -- COVID-19 in the United States of America -- Canada -- Mexico -- Peru -- Brazil -- Colombia -- Europe -- Russia -- Ukraine -- Italy -- Poland -- South Africa -- Antarctica -- References -- Chapter 3: Clinical Symptoms and Course of COVID-19 -- SARS-CoV-2 Transmission -- Virus Replication -- Immunological Responses and Cytokine Storm (CS) -- Virus Variants and Associated Evolution in the Clinical Course -- Clinical Stages of COVID-19 [21] -- Mild and Asymptomatic Stage -- Symptomatic Stage -- Severe Disease -- Acute Respiratory Distress Syndrome/Critical Stage -- Clinical Symptoms of COVID-19 -- General Symptoms in the Early, Asymptomatic and Mild Infection -- Respiratory Manifestations -- Extra-Respiratory Manifestations -- Hematologic Abnormalities -- Prothrombotic Events -- Cardiovascular Involvement

-- Neurological and Neuropsychiatric Manifestations -- Kidney Involvement -- Gastrointestinal and Hepatic Involvement -- Skin Associated COVID-19 Symptoms -- COVID-19 in Children -- Long COVID-19 -- Conclusions -- References -- Chapter 4: Risk Factors of Developing COVID-19 and its Severe Course -- COVID-19 and Related Cardiovascular Risk Factors -- Age -- Sex -- Smoking -- Diabetes -- Obesity -- Hypertension -- Dyslipidemia -- Chronic Kidney Disease.

Additional Markers of Increased CV Disease Risk in COVID-19 -- References -- Chapter 5: Prognosis in COVID-19 Patients: Statistics, Risk Factors -- Introduction -- Demographic Features -- Age and Sex -- Ethnicity -- Clinical Symptoms -- Comorbidities and the Course of COVID-19 -- Hypertension -- Diabetes Mellitus -- Obesity -- Chronic Obstructive Pulmonary Disease (COPD) -- Chronic Kidney Disease -- Cancer -- Special Conditions and Populations of Patients and the COVID-19 Course -- Smoking -- Pregnancy -- Children -- Selected Laboratory Parameters Values and the COVID-19 Course -- Leukocyte Counts -- Lymphocyte Counts -- Neutrophil Counts -- Platelet Counts -- C-Reactive Protein (CRP) -- Procalcitonin (PCT) -- Lactate Dehydrogenase (LDH) -- Interleukin 6 (IL-6) -- D-Dimer -- Ferritin -- Albumin -- Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) -- Cardiac Troponin -- Complications -- Reinfection -- Conclusions and Take-Home Message -- References -- Part II: Cardiovascular Complications of the Acute Phase of COVID-19 -- Chapter 6: Myocardial Injury in COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment) -- Introduction -- Definition of COVID-19 Induced Myocardial Injury -- Epidemiology -- Pathogenesis of Myocardial Injury in COVID-19 Patients -- Biomarkers Assessment of Myocardial Injury -- Cardiac Troponin -- Myocardial and Systemic Inflammation -- Other Biomarkers -- Paraclinical Assessment of Myocardial Injury -- ECG -- Cardiac Ultrasound -- Coronary Angiography -- Computed Tomography Angiography (CTA) -- Cardiac MRI -- Follow-Up and Treatment -- Prognosis -- Conclusions -- References -- Chapter 7: Acute Coronary Syndrome: Destabilization of Atherosclerotic Plaque in COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, and Treatment). COVID-19: Short Clinical Characteristics Through the Prism of Cardiology -- Epidemiology and Risk of ACS During SARS-CoV-2 Infection -- ACS During SARS-CoV-2 Infection and Prognosis -- Pathogenesis of ACS Induced by SARS-CoV-2 Infection -- Diagnostics and Treatment Aspects -- STEMI: ESC Guidance for the Diagnosis and Management of Cardiovascular Disease During the COVID-19 Pandemic [101] -- NSTEMI: ESC Guidance for the Diagnosis and Management of Cardiovascular Disease During the COVID-19 Pandemic [101] -- ACS Prevention -- Conclusions -- References -- Chapter 8: Acute Vascular Injury in COVID-19 -- Introduction -- Pathophysiology -- Clinical Presentation -- Respiratory -- Cardiovascular -- Central Nervous System -- Gastrointestinal -- Renal -- Dermatological -- Systemic Vasculitis -- Vaccine-Related Complications -- Treatment -- Anticoagulation -- Acute Coronary Syndrome -- Ischemic Stroke -- Venous Thromboembolism, DVT, and PE -- Acute Limb Ischemia -- Prophylaxis -- Anticoagulation -- Anti-Inflammatory Therapies -- Statins -- RAAS Inhibition -- Conclusion -- References -- Chapter 9: Heart Failure and Acute Circulatory Failure in COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment) -- Epidemiology -- Influence on Prognosis -- Pre-existing HF -- New Onset of HF -- Cardiogenic Shock -- Pathogenesis -- Direct Injury -- Systemic Inflammation -- Hypoxic

Injury -- Endothelial Dysfunction-Induced Coagulation Disorders -- Treatment -- Chronic Heart Failure Treatment -- Acute Heart Failure Treatment -- References -- Chapter 10: Cardiomyopathy in COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment) -- Introduction -- Heart Failure, Cardiomyopathies and COVID-19 -- Stress-Induced Cardiomyopathy and COVID-19 -- Dilated Cardiomyopathy and COVID-19 -- Hypertrophic Cardiomyopathy. Restrictive Cardiomyopathy and Arrhythmogenic Right Ventricular Cardiomyopathy in COVID-19 -- Cardiomyopathies and COVID-19 Vaccines -- Summary -- References -- Chapter 11: Arrhythmias in COVID-19 -- Epidemiology -- Influence on Prognosis -- Pathogenesis -- Treatment -- References -- Chapter 12: Thromboembolic Events in COVID-19 -- Epidemiology -- Pathogenesis -- The Diagnosis of VTE in COVID-19 -- Treatment -- Thromboprophylaxis in Patients with COVID-19 -- Influence on Prognosis -- Conclusions -- References -- Chapter 13: Stroke in COVID-19 -- Introduction -- Ischemic Stroke (IS) and Transient Ischemic Attack (TIA) in COVID-19 Pandemic -- Epidemiology of IS and TIA During COVID-19 Pandemic -- Description of IS in COVID-19 Positive Patients -- Clinical, Etiological, and Imaging Features of COVID-19 Positive IS Patients -- Management of COVID-19 Positive Patients with IS -- Outcome of COVID-19 Positive Patients with IS -- Pathogenesis -- Conclusions -- Hemorrhagic Stroke (HS) in COVID-19 Pandemic -- Epidemiology of HS During COVID-19 Pandemic -- Intracerebral Hemorrhage (ICH) -- Clinical Features of ICH in COVID-19 Positive Patients -- Comorbidities of COVID-19 Positive Patients with ICH -- Management of COVID-19 Positive Patients with ICH -- Course and Outcome of HS in COVID-19 Positive Patients -- Pathogenesis -- Conclusion -- Subarachnoid Hemorrhage (SAH) in COVID-19 Pandemic -- Epidemiology During COVID-19 Pandemic -- Clinical Features of COVID-19 Positive SAH Patients -- Course and Outcome of COVID-19 Positive Patients with SAH -- Pathogenesis -- Conclusion -- Cerebral Venous Thrombosis (CVT) in COVID-19 Positive Patients -- Epidemiology of CVT During COVID-19 Pandemic -- Clinical Features of CVT in COVID-19 Positive Patients -- Course and Outcome of CVT in COVID-19 Positive Patients -- Pathogenesis -- Conclusion -- References.

Chapter 14: Pulmonary Embolism After COVID-19 (Epidemiology, Influence on Prognosis, Pathogenesis, Treatment) -- Introduction -- Epidemiology -- Incidence, Risk Factors -- Pathogenesis -- Thromboembolic Event Prevention and Management in COVID-19 Pneumonia Patients -- Prophylactic Anticoagulation in Severe Hospitalized Patients -- Prophylactic Anticoagulation in Mild to Moderate Patients -- Prophylactic Treatment in Outpatient -- Anticoagulation After Discharge from COVID-19 Hospitalization -- Therapeutic Anticoagulation of Incident Thromboembolic Event -- Medium- and Long-Term Prognosis After a Venous Thrombotic Event -- Conclusion -- References -- Chapter 15: Interaction of Anti-COVID-19 Drugs with Cardiovascular Therapy -- Statins -- -Blockers -- Antihypertensive Drugs -- Natural Drugs -- References -- Part III: Influence of the Treatment of Cardiovascular Diseases on the Course of COVID-19 -- Chapter 16: Beyond the Vaccines-Bioactive Lipids in COVID-19 -- Introduction -- Bioactive Lipids LA and AA Can Inactivate SARS-CoV-2 -- Immunocytes and AA -- M1 and M2 Macrophages and Lipids -- Interaction(s) Among Desaturases, COX, LOX, n-3, and n-6 Fatty Acids and Their Metabolites and Cytokines -- PGE2 and LXA4 Interact with each Other to Control Inflammation and Its Resolution -- Conclusions and Therapeutic Implications -- References

-- Chapter 17: Statins and COVID-19 (Mechanism of Action, Effect on Prognosis) -- Statins and COVID-19: Mechanism of Action -- Direct Effect of Statins -- Indirect Effect of Statins -- Statins and COVID-19: Effect on Prognosis -- COVID-19 and Familial Hypercholesterolemia -- References -- Chapter 18: COVID-19 and Antihypertensive Treatment -- Introduction -- COVID-19 and Hypertension -- COVID-19 and Antihypertensive Drug Treatment -- Study Limitations -- Blood Pressure Values, Blood Pressure Control, and COVID-19 Pandemic. COVID-19 and Hypertension Guidelines.

---